However, co-treatment of gastric cancer cells with casticin (1.0 μmol/l) and TRAIL (25 ng/ml or 50 ng/ml) markedly increased the cytotoxic effects compared with treatment with casticin or TRAIL alone (Figure 1C). The gene discussed is TNFSF10; the disease is gastric cancer.